Search results
Results From The WOW.Com Content Network
Treatment and management of COVID-19. The treatment and management of COVID-19 combines both supportive care, which includes treatment to relieve symptoms, fluid therapy, oxygen support as needed, [1] [2] [3] and a growing list of approved medications. Highly effective vaccines have reduced mortality related to SARS-CoV-2; however, for those ...
Remdesivir, sold under the brand name Veklury, [13] [14] is a broad-spectrum antiviral medication developed by the biopharmaceutical company Gilead Sciences. [15] It is administered via injection into a vein. [16] [17] During the COVID‑19 pandemic, remdesivir was approved or authorized for emergency use to treat COVID‑19 in numerous countries. [18]
COVID-19 drug development is the research process to develop preventative therapeutic prescription drugs that would alleviate the severity of coronavirus disease 2019 (COVID-19).
Pfizer said its latest mid-to-late-stage trial will enroll 1,140 non-hospitalized adults diagnosed with coronavirus infection who are not at risk of severe illness. Patients in the trial will be ...
In December 2021, nirmatrelvir/ritonavir was granted emergency use authorization (EUA) by the United States Food and Drug Administration (FDA) to treat COVID‑19. [13] [21] It was approved in the United Kingdom later that month, [22] and in the European Union and Canada in January 2022. [15] [23] [24] In May 2023, it was approved in the US to treat mild-to-moderate COVID‑19 in adults who ...
The Oxford–AstraZeneca COVID‑19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus in order to prevent COVID-19 in adults aged 18 years and older. [1] The medicine is administered by two 0.5 ml (0.017 US fl oz) doses given by intramuscular injection into the deltoid muscle (upper arm).
Molnupiravir, sold under the brand name Lagevrio, is an antiviral medication that inhibits the replication of certain RNA viruses. [7] It is used to treat COVID‑19 in those infected by SARS-CoV-2. [7] It is taken by mouth.
This is the list of Schedule III controlled substances in the United States as defined by the Controlled Substances Act at 21 U.S.C. § 812 (c) and 21 CFR 1308.13. The following findings are required for substances to be placed in this schedule: [1]